Endocrine therapy or chemotherapy as first-line therapy in hormone receptor–positive HER2-negative metastatic breast cancer patients
-
Published:2018-05
Issue:
Volume:95
Page:93-101
-
ISSN:0959-8049
-
Container-title:European Journal of Cancer
-
language:en
-
Short-container-title:European Journal of Cancer
Author:
Jacquet E., Lardy-Cléaud A., Pistilli B., Franck S., Cottu P.ORCID, Delaloge S., Debled M., Vanlemmens L., Leheurteur M., Guizard A.V., Laborde L., Uwer L., Jacot W., Berchery D., Desmoulins I., Ferrero J.M., Perrocheau G., Courtinard C., Brain E.ORCID, Chabaud S., Robain M., Bachelot T.
Funder
R&D UNICANCER-ESME
Subject
Cancer Research,Oncology
Reference24 articles.
1. Third consensus on medical treatment of metastatic breast cancer;Beslija;Ann Oncol,2009 2. A review of systematic reviews of the cost-effectiveness of hormone therapy, chemotherapy, and targeted therapy for breast cancer;Diaby;Breast Cancer Res Treat,2015 3. Breast cancer with synchronous metastases: trends in survival during a 14-year period;Andre;J Clin Oncol,2004 4. ESO-ESMO 2nd international consensus guidelines for advanced breast cancer (ABC3);Cardoso;Ann Oncol,2017 5. Fulvestrant 500 mg versus anastrozole 1 mg for hormone receptor-positive advanced breast cancer (FALCON): an international, randomised, double-blind, phase 3 trial;Robertson;Lancet,2016
Cited by
54 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
|
|